What is EN Rx?
EN Rx LLC is a specialized provider of innovative environmental solutions designed to tackle complex challenges and enhance property value. The company's core offerings include the Vertebrae Well System for effective remediation and assessment in difficult-to-access areas, and the EN Rx Reagent, a potent and stable oxidation agent. Serving environmental consultants, regulators, and various stakeholders in remediation projects, EN Rx aims to revolutionize environmental work through safer and more efficient outcomes.
How much funding has EN Rx raised?
EN Rx has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in EN Rx
PPP
Public-Private Partnership
What's next for EN Rx?
As a company operating within a large-scale, late-stage funding environment, EN Rx is strategically positioned for significant expansion. The recent major strategic investment likely signals a focus on scaling operations, enhancing its technological capabilities, and potentially broadening its market reach. Future developments may involve further integration of its innovative systems, such as the Vertebrae Well System and EN Rx Reagent, into larger-scale environmental projects, solidifying its role as a leader in advanced remediation technologies.
See full EN Rx company page
